Pancreatic enzymes and abdominal adipose tissue distribution in new-onset prediabetes/diabetes after acute pancreatitis

Table 2 Differences in abdominal fat phenotypes between the study groups

Fat phenotype	Overall1	T2DM vs NODAP	T2DM vs healthy controls	NODAP vs healthy controls
Intra-pancreatic fat (%)
Model 1	< 0.001	0.290	< 0.001	0.001
Model 2	0.002	0.555	0.001	0.004
Model 3	0.001	0.440	0.001	0.001
Model 4	0.003	0.187	0.002	0.012
Liver fat (%)
Model 1	0.416	0.806	0.322	0.211
Model 2	0.681	0.457	0.983	0.465
Model 3	0.556	0.998	0.393	0.312
Model 4	0.612	0.428	0.329	0.801
Skeletal muscle fat (%)
Model 1	0.348	0.148	0.516	0.420
Model 2	0.329	0.137	0.455	0.489
Model 3	0.585	0.319	0.692	0.544
Model 4	0.477	0.243	0.551	0.460
Visceral fat (cm3)
Model 1	< 0.001	0.093	< 0.001	0.001
Model 2	0.010	0.596	0.005	0.012
Model 3	0.001	0.249	< 0.001	0.003
Model 4	0.005	0.787	0.012	0.003
Subcutaneous fat (cm3)
Model 1	0.013	0.214	0.003	0.082
Model 2	0.740	0.488	0.508	0.987
Model 3	0.038	0.245	0.012	0.081
Model 4	0.034	0.063	0.009	0.301

¹Overall P values were from one-way analysis of variance in model 1 (unadjusted) and one-way analysis of covariance in models 2-4 (adjusted as described below). Data are presented as P values. Fisher’s least significant difference method was used in pair-wise comparison. Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, triglycerides, and glycated hemoglobin A1c; Model 4: Adjusted for age, sex, triglycerides, glycated hemoglobin A1c, use of antidiabetic medications, average weekly alcohol consumption, and smoking status. T2DM: Type 2 prediabetes/diabetes mellitus; NODAP: New-onset prediabetes/diabetes after acute pancreatitis.